FR2730232B1 - Anhydrate de chlorhydrate de paroxetine pratiquement depourvu de propane-2-ol lie, son application en therapeutique - Google Patents

Anhydrate de chlorhydrate de paroxetine pratiquement depourvu de propane-2-ol lie, son application en therapeutique

Info

Publication number
FR2730232B1
FR2730232B1 FR9601297A FR9601297A FR2730232B1 FR 2730232 B1 FR2730232 B1 FR 2730232B1 FR 9601297 A FR9601297 A FR 9601297A FR 9601297 A FR9601297 A FR 9601297A FR 2730232 B1 FR2730232 B1 FR 2730232B1
Authority
FR
France
Prior art keywords
propane
lie
substantially free
therapeutic application
paroxetine hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9601297A
Other languages
English (en)
Other versions
FR2730232A1 (fr
Inventor
Victor Witold Jacewicz
Neal Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2730232(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9502297.6A external-priority patent/GB9502297D0/en
Priority claimed from GBGB9503112.6A external-priority patent/GB9503112D0/en
Priority claimed from GBGB9509807.5A external-priority patent/GB9509807D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of FR2730232A1 publication Critical patent/FR2730232A1/fr
Application granted granted Critical
Publication of FR2730232B1 publication Critical patent/FR2730232B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR9601297A 1995-02-06 1996-02-02 Anhydrate de chlorhydrate de paroxetine pratiquement depourvu de propane-2-ol lie, son application en therapeutique Expired - Fee Related FR2730232B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9502297.6A GB9502297D0 (en) 1995-02-06 1995-02-06 Novel compound
GBGB9503112.6A GB9503112D0 (en) 1995-02-17 1995-02-17 Novel compound
GBGB9509807.5A GB9509807D0 (en) 1995-05-15 1995-05-15 Novel compounds

Publications (2)

Publication Number Publication Date
FR2730232A1 FR2730232A1 (fr) 1996-08-09
FR2730232B1 true FR2730232B1 (fr) 1997-08-01

Family

ID=27267578

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9601297A Expired - Fee Related FR2730232B1 (fr) 1995-02-06 1996-02-02 Anhydrate de chlorhydrate de paroxetine pratiquement depourvu de propane-2-ol lie, son application en therapeutique

Country Status (47)

Country Link
EP (3) EP0808314B1 (fr)
JP (2) JP2915338B2 (fr)
KR (1) KR100289885B1 (fr)
CN (3) CN1289496C (fr)
AR (2) AR001982A1 (fr)
AT (1) AT407528B (fr)
AU (2) AU701518C (fr)
BE (1) BE1009112A3 (fr)
BG (1) BG62967B1 (fr)
BR (1) BR9600534A (fr)
CA (4) CA2168829C (fr)
CH (3) CH688353A5 (fr)
CZ (1) CZ297171B6 (fr)
DE (3) DE69621777T2 (fr)
DK (2) DK11996A (fr)
DZ (1) DZ1989A1 (fr)
ES (1) ES2114471B1 (fr)
FI (3) FI111544B (fr)
FR (1) FR2730232B1 (fr)
GR (1) GR1002466B (fr)
HK (1) HK59397A (fr)
HU (1) HUP9600255A1 (fr)
IE (1) IE80500B1 (fr)
IL (1) IL117035A (fr)
IT (1) IT1289532B1 (fr)
LU (1) LU88711A1 (fr)
LV (1) LV11618B (fr)
MA (1) MA23802A1 (fr)
MC (1) MC2411A1 (fr)
MX (1) MX9600484A (fr)
MY (1) MY132529A (fr)
NL (1) NL1002248C2 (fr)
NO (3) NO301009B1 (fr)
NZ (1) NZ280943A (fr)
OA (1) OA10261A (fr)
PL (1) PL189247B1 (fr)
PT (1) PT101827B (fr)
RO (1) RO112426B1 (fr)
RU (1) RU2125052C1 (fr)
SE (1) SE521084C2 (fr)
SG (1) SG43787A1 (fr)
SI (2) SI21923B (fr)
SK (1) SK283608B6 (fr)
TR (1) TR199600096A2 (fr)
TW (1) TW503238B (fr)
UA (1) UA49796C2 (fr)
WO (1) WO1996024595A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3882224B2 (ja) 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1384720A1 (fr) 1996-06-13 2004-01-28 SUMIKA FINE CHEMICALS Co., Ltd. Procédé de séchage pour le chlorhydrate de paroxetine
EP0937152A2 (fr) * 1996-07-15 1999-08-25 Smithkline Beecham Plc Criblage et utilisation d'esterase pour dedoublement stereospecifique
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
CA2193939C (fr) * 1996-12-24 2002-02-12 K.S. Keshava Murthy Forme utile de chlorhydrate de paroxetine anhydre
DE69704679T2 (de) * 1997-06-10 2001-09-13 Synthon Bv 4-phenylpiperidin-derivate
ES2150808T3 (es) * 1997-08-08 2000-12-01 Aventis Pharma Gmbh Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico.
GB9726907D0 (en) * 1997-12-19 1998-02-18 Smithkline Beecham Plc Novel compounds
WO1999047519A1 (fr) * 1998-03-16 1999-09-23 Smithkline Beecham Plc Forme cristalline de la paroxetine
GB9806312D0 (en) * 1998-03-24 1998-05-20 Smithkline Beecham Plc Novel formulations
AU2003200534B2 (en) * 1998-03-24 2004-12-02 Smithkline Beecham Plc Paroxetine compositions
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
JP3796351B2 (ja) 1998-04-13 2006-07-12 住友化学株式会社 パロキセチン塩酸塩無水和物の乾燥方法
GB9812941D0 (en) * 1998-06-16 1998-08-12 Smithkline Beecham Plc Method of treatment
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2138937B1 (es) 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
AP2001002072A0 (en) * 1998-08-07 2001-03-31 Smithkline Becham P L C Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride
GB9824298D0 (en) * 1998-11-05 1998-12-30 Smithkline Beecham Plc Novel process
GB9826176D0 (en) * 1998-11-28 1999-01-20 Smithkline Beecham Plc Novel process
GB9826175D0 (en) * 1998-11-28 1999-01-20 Smithkline Beecham Plc Novel process
GB9826178D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
AU1397900A (en) * 1998-11-30 2000-06-19 Smithkline Beecham Plc Mixed paroxetine propan-2-ol solvates
GB9826171D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel compounds
GB9826242D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826180D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9828767D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
WO2000054775A1 (fr) * 1999-03-12 2000-09-21 Basf Ag Forme galenique pharmaceutique stable pour anhydrate de paroxetine
GB9914583D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9919001D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel process
GB9923446D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
GB9923439D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
GB9923445D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
JPWO2002022609A1 (ja) * 2000-09-14 2004-01-22 旭硝子株式会社 実質的に有機溶媒を含まないパロキセチン塩類の製造方法
CA2476723A1 (fr) * 2002-02-22 2003-09-04 Gideon Pilarski Preparation de paroxetine impliquant de nouveaux intermediaires
US7563930B2 (en) * 2005-11-22 2009-07-21 Teva Pharmaceutical Industries Ltd Crystal forms of Cinacalcet HCI and processes for their preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
AU658155B2 (en) * 1990-11-24 1995-04-06 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, or anorexia
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
CN1216055C (zh) 2005-08-24
CN1310180A (zh) 2001-08-29
CZ32096A3 (en) 1996-08-14
RO112426B1 (ro) 1997-09-30
AU4786496A (en) 1996-08-27
SI9600036A (en) 1996-10-31
CN1636993A (zh) 2005-07-13
DK11996A (da) 1996-08-07
DZ1989A1 (fr) 2002-10-15
NO301009B3 (fr) 2003-01-06
ITMI960203A0 (fr) 1996-02-05
SK283608B6 (sk) 2003-10-07
NO301009B1 (no) 1997-09-01
AR001982A1 (es) 1998-01-07
IT1289532B1 (it) 1998-10-15
FR2730232A1 (fr) 1996-08-09
KR960031409A (ko) 1996-09-17
CA2211522C (fr) 1999-12-07
CA2210023A1 (fr) 1996-08-07
AT407528B (de) 2001-04-25
CA2168829A1 (fr) 1996-08-07
NO970939D0 (no) 1997-02-28
HK59397A (en) 1997-05-16
NO20015070D0 (no) 2001-10-18
EP1136490B1 (fr) 2004-01-07
HU9600255D0 (en) 1996-03-28
DE19603797A1 (de) 1996-08-14
LV11618A (lv) 1996-12-20
PT101827B (pt) 1997-08-29
SI9600036B (sl) 2006-12-31
NO970939L (no) 1996-08-07
KR100289885B1 (ko) 2001-05-15
SK14396A3 (en) 1996-11-06
IL117035A (en) 2000-02-29
BG62967B1 (bg) 2000-12-29
JPH08245620A (ja) 1996-09-24
CH689229A5 (de) 1998-12-31
CH688353A5 (de) 1997-08-15
EP1136490A1 (fr) 2001-09-26
ITMI960203A1 (it) 1997-08-05
CH689804A5 (de) 1999-11-30
WO1996024595A1 (fr) 1996-08-15
UA49796C2 (uk) 2002-10-15
IL117035A0 (en) 1996-09-12
BG100333A (bg) 1996-08-30
TR199600096A2 (tr) 1996-08-21
CA2210023C (fr) 1999-02-09
AU701518B2 (en) 1999-01-28
HUP9600255A1 (en) 1997-03-28
ES2114471B1 (es) 1999-08-16
DE19603797C2 (de) 1998-11-12
SE521084C2 (sv) 2003-09-30
IE960104A1 (en) 1996-08-07
CA2211522A1 (fr) 1996-08-07
SG43787A1 (en) 1997-11-14
RU2125052C1 (ru) 1999-01-20
FI960519A0 (fi) 1996-02-05
FI960519A (fi) 1996-08-07
MX198371B (fr) 2000-08-29
MA23802A1 (fr) 1996-10-01
CA2168829C (fr) 1997-12-16
CA2210022A1 (fr) 1996-08-07
SE9600406L (sv) 1996-08-07
TW503238B (en) 2002-09-21
SI21923B (sl) 2006-12-31
JP2915338B2 (ja) 1999-07-05
EP1378508A1 (fr) 2004-01-07
AU701518C (en) 2006-12-07
SI21923A (sl) 2006-06-30
NL1002248C2 (nl) 1996-09-11
LU88711A1 (fr) 1996-08-23
AR036856A2 (es) 2004-10-06
NZ280943A (en) 1997-01-29
PL189247B1 (pl) 2005-07-29
PL312646A1 (en) 1996-08-19
SE9600406D0 (sv) 1996-02-05
CN1289496C (zh) 2006-12-13
FI20030162A (fi) 2003-02-03
NO20015070L (no) 1996-08-07
CN1143643A (zh) 1997-02-26
GR1002466B (el) 1996-11-06
BE1009112A3 (fr) 1996-11-05
MC2411A1 (fr) 1996-12-02
MX9600484A (es) 1997-01-31
LV11618B (en) 1997-04-20
DE69621777D1 (de) 2002-07-18
EP0808314B1 (fr) 2002-06-12
CA2210022C (fr) 2005-09-13
JPH11228571A (ja) 1999-08-24
DE69631298D1 (de) 2004-02-12
NL1002248A1 (nl) 1996-08-06
NO960472L (no) 1996-08-07
OA10261A (en) 1997-09-19
IE80500B1 (en) 1998-08-12
ATA21096A (de) 2000-08-15
PT101827A (pt) 1996-09-30
FI20030370A (fi) 2003-03-12
DE69621777T2 (de) 2003-01-02
MY132529A (en) 2007-10-31
NO311519B1 (no) 2001-12-03
CZ297171B6 (cs) 2006-09-13
FI111544B (fi) 2003-08-15
DK200100223A (fr) 2001-02-12
NO960472D0 (no) 1996-02-05
CN1090187C (zh) 2002-09-04
EP0808314A1 (fr) 1997-11-26
BR9600534A (pt) 1997-05-13
AU4332896A (en) 1996-08-15
DE69631298T2 (de) 2004-11-18
ES2114471A1 (es) 1998-05-16

Similar Documents

Publication Publication Date Title
FR2730232B1 (fr) Anhydrate de chlorhydrate de paroxetine pratiquement depourvu de propane-2-ol lie, son application en therapeutique
PL332432A1 (en) Oxadiazoles, method of obtaining them as well as their application as therapeutic agents
DE69627228D1 (de) Biokompatible medizinische Elektrodenleitung
DE69618176D1 (de) Weiches behandeltes tissue
FI972681A0 (fi) Kynsien sientenvastainen käsittely
DE69630335D1 (de) Implantierbarer Herzschrittmacher
BR9604906A (pt) Agentes anti-fúngicos de peptídeo cíclico
PL327171A1 (en) Novel derivatives of phenyl amine, method of obtaining them and their application as therapeutic agents
DE69631727D1 (de) Implantierbarer Herzschrittmacher
DK0835254T3 (da) Oxazolidinonderivater, deres fremstilling og deres terapeutiske anvendelse
GB2297550B (en) Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
DE69637548D1 (de) MENSCHLICHE DNAse I VARIANTEN
FR2742152B1 (fr) Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique
IL136590A0 (en) Process for preparation of paroxetine hydrochloride
FR2755013B1 (fr) Nouvelle application therapeutique des antagonistes de la substance p
FR2765580B1 (fr) Derives de (1h-imidazol-4-yl)piperidine, leur preparation et leur application en therapeutique
DE69625379D1 (de) Salze des n-[4-oxo-2-(1h-tetrazoyl-5-yl)-4h-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamids
NO962385D0 (no) Terapeutiske amider
FR2765221B1 (fr) Derives de 4-[(1h-imidazol-4-yl)piperidin-1-yl]anilide, leur preparation et leur application en therapeutique
KR960030483U (ko) 수지침용 마사지구
AU740561C (en) Paroxetine hydrochloride anhydrate
FR2737723B1 (fr) Derives de 1-(2-(1h-inden-3-yl)ethyl)-4-(naphtalen-1-yl)- piperazine, leur preparation et leur application en therapeutique
FR2738566B1 (fr) Derives de 4-(cycloalkyl)piperidines et de 4-(cycloalkylalkyl)piperidines, leur preparation et leur application en therapeutique
KR970014264U (ko) 실린더의 쿳션장치
UA25798A (uk) Спосіб лікуваhhя відкритокутової глаукоми

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20131031